Company Announcements

SomaLogic announced collaborative projects with the University of Oxford to discover and characterize protein biomarkers.

SomaLogic announced in March the receipt of up to $60.5 million in debt and equity financing from Visium Healthcare Partners.

In February, Gen9 and SynbiCITE, a UK-based Innovation and Knowledge Centre, partnered to provide SynbiCITE access to the BioFab platform for gene synthesis.

Caribou Bioscience granted rights in February for Integrated DNA Technologies to commercialize its CRISPR-Cas9 reagents for research use.

DiscoverX partnered in February with the Structural Genomics Consortium to develop chemical probes for the unexplored human kinome and to promote open sharing of these probes.

EpiCypher announced in February the addition of five distributors in 2015, bringing the total to 16 outside of the US.

Bio-Techne’s R&D Systems and Novus Biologicals brand joined the Affinity Binder Knockdown Initiative.

For the half year ending December 31, 2015, Abcam sales grew 18.0%, 17.2% excluding currency, to £78.8 million ($121.2 million = £0.65 = $1) (see IBO 3/15/16). All sales below exclude currency. Catalogue revenue, which accounted for 93% of sales, improved 15.7%, including 32% growth each for RabMAb and non–primary antibody sales. Catalogue sales in China and Rest of Asia jumped 52.2% and 22.5% to make up 13% and 7%, respectively. Sales in the Americas, EMEA and Japan all grew over double digits to account for 42%, 30% and 7% of Catalogue sales, respectively. Total adjusted operating margin fell 470 basis points to 30.7% due to increased investments.

Abcam announced that COO Jim Warwick will resign from its Board by the end of the year.

NanoString Technologies will use Cell Signaling Technology’s antibodies in its 3D Biology Protein Profiling Panels.

Product Introductions

In February, Rockland Immunochemicals, in collaboration with the Wister Institute, made available a new collection of human melanoma cell lines. More than 100 of the lines will be exclusively distributed by Rockland.

Agilent Technologies announced early access to custom CRISPR guideRNA, branded as SureGuide gRNA libraries, using its oligo library synthesis platform.

AMSBIO introduced the Skeletal Muscle Differentiation kit, calling it the world’s first kit to differentiate human iPSCs into functional myotubes.

ALPCO launched its new InhibiScreen Basophil Activation Test for the evaluation of kinase inhibitors during early drug development.